Close Menu

NEW YORK, Dec. 13 – Biosimulation company Entelos has agreed to prioritize asthma drug candidates for Pfizer. 

Entelos of Menlo Park, Calif., said Wednesday it would use its Asthma PhysioLab technology to analyze how people with and without asthma react to the treatments and to determine the appropriate treatment dosages. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.